Effectiveness of Phosphodiesterase-5 Inhibitor Therapy for Portopulmonary Hypertension

Jolene H Fisher; Sindhu R Johnson; Cathy Chau; Amie T Kron; John T Granton

doi:10.1155/2015/810376

Canadian Respiratory Journal (Jan 2015)

Effectiveness of Phosphodiesterase-5 Inhibitor Therapy for Portopulmonary Hypertension

Jolene H Fisher,
Sindhu R Johnson,
Cathy Chau,
Amie T Kron,
John T Granton

Affiliations

Jolene H Fisher: University Health Network Pulmonary Hypertension Program, Canada
Sindhu R Johnson: University Health Network Pulmonary Hypertension Program, Canada
Cathy Chau: Division of Rheumatology, Department of Medicine, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
Amie T Kron: Division of Rheumatology, Department of Medicine, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
John T Granton: University Health Network Pulmonary Hypertension Program, Canada

DOI: https://doi.org/10.1155/2015/810376
Journal volume & issue: Vol. 22, no. 1
pp. 42 – 46

Abstract

Read online

BACKGROUND: Portopulmonary hypertension is associated with significant morbidity and mortality. Phosphodiesterase-5 inhibitor therapy is efficacious in other causes of WHO group I pulmonary arterial hypertension.

Published in Canadian Respiratory Journal

ISSN: 1198-2241 (Print); 1916-7245 (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system
Website: https://onlinelibrary.wiley.com/journal/7503

About the journal